7-5/2013/EU/WC-0144
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan,Kotla Road,
New Delhi-110002
Dated:

08 JUN 2022

To

M/s. Cipla Limited,
D-7, MIDC, Industrial Area, Kurkumbh,
Taluka: Daund, District: Pune –Zone4- 413 802
Maharashtra, India

Subject:- Written Confirmation of M/s.Cipla Limited, D-7, MIDC, Industrial Area, Kurkumbh, Taluka: Daund, District: Pune- Zone4- 413 802, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application No. WC/RE/2022/2855 submitted to CDSCO, West Zone office Mumbai and the recommendation received from DDC(I), West Zone Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
1	31	08 JUN 2022	08.09.2025
2	04	08 JUN 2022	08.09.2025

Yours faithfully,

(Dr. V.G. Somani)
Drugs Controller General (India)

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : WC-0144

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. **Name and address of site: M/s.Cipla Limited,**
D-7, MIDC, Industrial Area, Kurkumbh,
Taluka: Daund, District: Pune -Zone4- 413 802
Maharashtra, India

2. **Manufacturer's licence number**: 28-PD/42 and 25-PD/46

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

As per List enclosed as Annexure-1 & 2

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (=GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 29.09.2021, 30.09.2021 & 01.10.2021

The Written Confirmation remains valid until: 08.09.2025.

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: **Central Drugs Standard Control Organisation**
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Dr. V.G. Somani
Drugs Controller General (India)

E-mail: dci@nic.in,
Telephone no.: +91-11-23236965
Fax no.: +91-11-23236

Signature 08 JUN 2022

Stamp of the authority and date

Central Drugs Standard Control Organization
Ministry of Health & Family Welfare, Govt. of India

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. :

Annexure-1
WC-0144

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: **M/s. Cipla Limited,**
D-7, MIDC, Industrial Area, Kurkumbh,
Taluka: Daund, District: Pune- Zone4- 413 802
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Albendazole USP	Manufacturing & Packing
2.	Alendronate Sodium Trihydrate USP	Manufacturing & Packing
3.	Arformoterol Tartrate IH	Manufacturing & Packing
4.	Atazanavir Sulfate Ph.Eur	Manufacturing & Packing
5.	Budesonide BP/Ph.Eur/USP	Manufacturing & Packing
6.	Carvedilol BP/Ph.Eur/USP	Manufacturing & Packing
7.	Celecoxib BP/Ph.Eur/USP	Manufacturing & Packing
8.	Ciclesonide IH	Manufacturing & Packing
9.	Cinacalcet Hydrochloride IH	Manufacturing & Packing
10.	Citalopram Hydrobromide BP/Ph.Eur/USP	Manufacturing & Packing
11.	Darunavir Ethanolate IH	Manufacturing & Packing
12.	Entecavir Monohydrate BP/Ph. Eur/USP	Manufacturing & Packing
13.	Famciclovir IH	Manufacturing & Packing
14.	Fluconazole BP/Ph.Eur/USP	Manufacturing & Packing
15.	Fluticasone Propionate BP/Ph.Eur/USP	Manufacturing & Packing
16.	Formoterol Fumarate Dihydrate BP/Ph.Eur/USP	Manufacturing & Packing
17.	Lamivudine BP/Ph.Eur/USP	Manufacturing & Packing
18.	Mebendazole USP	Manufacturing & Packing
19.	Meloxicam BP/Ph.Eur/USP	Manufacturing & Packing
20.	Mometasone Furoate BP/Ph.Eur/USP	Manufacturing & Packing
21.	Mometasone Furoate Monohydrate BP/Ph.Eur	Manufacturing & Packing
22.	Olanzapine BP/Ph.Eur/USP	Manufacturing & Packing
23.	Ondansetron Hydrochloride Dihydrate BP/Ph.Eur/USP	Manufacturing & Packing
24.	Ondansetron IH	Manufacturing & Packing
25.	Oseltamivir Phosphate Bp/Ph. Eur/USP	Manufacturing & Packing
26.	Pramipexole Dihydrochloride Monohydrate BP/Ph.Eur/USP	Manufacturing & Packing
27.	Ramipril BP/Ph.Eur/USP	Manufacturing & Packing
28.	Rizatriptan Benzoate BP/Ph. Eur/USP	Manufacturing & Packing
29.	Sodium Alendronate BP/Ph. Eur	Manufacturing & Packing
30.	Tiotropium Bromide Monohydrate BP/Ph.Eur	Manufacturing & Packing
31.	Zoledronic Acid IH	Manufacturing & Packing

ITEM(S) Thirty One (31) ONLY

The Written Confirmation remains valid until: 08.09.2025

Signature

08 JUN 2022

Stamp of the authority and date

Central Drugs Standard Control Organization • Ministry of Health & Family Welfare, Govt. of India

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. :

Annexure-2
WC-0144

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: **M/s. Cipla Limited,**
D-7, MIDC, Industrial Area, Kurkumbh,
Taluka: Daund, District: Pune- Zone4- 413 802
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Risedronate Sodium 2.5 Hydrate Ph.Eur/BP	Manufacturing & Packing
2.	Valganciclovir Hydrochloride USP	Manufacturing & Packing
3.	Beclometasone Dipropionate USP	Manufacturing & Packing
4.	Beclometasone Dipropionate Monohydrate BP/Ph.Eur	Manufacturing & Packing

ITEM(S) Four (04) ONLY

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: 08.09.2025.

Signature

Stamp of the authority and date

Central Drugs Standard Control Organization • Ministry of Health & Family Welfare, Govt. of India •

08 JUN 2022